Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab and Cladribine in CLL and SLL
NCT01446900Phase 2Terminated
- Sponsor
- European Institute of Oncology
- Start
- Jan 2011
- Primary completion
- Dec 2017
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of rituximab in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by European Institute of Oncology. Primary endpoint: Overall Response Rate at 17 months. Started Jan 2011; status: terminated.
02
Drugs
rituximab
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT01446900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01446900.